Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial.
Masatsugu HoriJun ZhuYan LiangDeepak L BhattJacqueline BoschStuart J ConnollyKeith A A FoxAldo MaggioniSalim YusufJohn William EikelboomPublished in: European heart journal (2022)
Asian compared with non-Asian patients with chronic CAD and/or PAD have higher rates of ICH and minor bleeding. The combination of rivaroxaban and aspirin vs. aspirin alone produces similar effects for MACE, modified ISTH major bleeding, and net clinical outcome but may be associated with higher rates of ICH in Asian patients.
Keyphrases
- low dose
- coronary artery disease
- cardiovascular events
- atrial fibrillation
- antiplatelet therapy
- end stage renal disease
- venous thromboembolism
- ejection fraction
- pulmonary embolism
- clinical trial
- chronic kidney disease
- newly diagnosed
- cardiovascular disease
- randomized controlled trial
- peritoneal dialysis
- prognostic factors
- acute coronary syndrome
- patient reported outcomes
- phase ii